Searched for
RANBAXY PROMOTERS
NCLAT quashes Ligare Aviation's insolvency; loan from Religare Enterprises round-tripping of moneyThe National Company Law Appellate Tribunal has cancelled insolvency proceedings against Ligare Aviation. The tribunal found the National C...- After 50 hearings, court reserves judgement in Daiichi-Fortis caseThe Delhi High Court has reserved its judgment in a significant arbitration case. Japanese drug maker Daiichi Sankyo is seeking to enforce ...
- Fortis liability case: Delhi HC says blame can't be shifted to third partyAmid ongoing legal disputes, the Delhi High Court is probing Fortis Healthcare's oversight concerning the sale of shares belonging to the S...
- Jacqueline Fernandez withdraws plea to turn approver in money laundering caseActor Jacqueline Fernandez has withdrawn her plea to become an approver in the Sukesh Chandrashekar money laundering case. The Enforcement ...
- ED opposes Jacqueline Fernandez's approver plea in Rs 200 crore laundering caseThe Enforcement Directorate has opposed actor Jacqueline Fernandez's request to become an approver in a Rs 200 crore money laundering case....
- SC dissatisfied over replies filed by ex-Ranbaxy promoters, will hear contempt petition on Apr 11A bench headed by Chief Justice Ranjan Gogoi said it will now straightaway hear the contempt petition against the Singh brothers.
- Ex-Ranbaxy promoters to respond to Daiichi Sankyo's allegations in arbitration caseJustice S Muralidhar has directed the brothers to file a reply to Daiichi's allegations before the next hearing of the case on March 6, whe...
- Daiichi acquires 20% from Ranbaxy promoters, hikes stake to over 50%Ranbaxy is now a subsidiary of Japanese drug major Daiichi Sankyo.
- Ranbaxy promoters may have to pay Rs 1k cr tax on Daiichi dealThe Securities and Exchange Board of India (Sebi) has rejected a plea from the promoters of Ranbaxy for a wavier of rules applicable to blo...
- Ranbaxy, Pfizer sign truce over LipitorRanbaxy has settled most of its patent disputes with Pfizer, allowing it to launch a generic version of Lipitor from November 30, 2011. Ran...
- Ranbaxy may go for bulk deal to save taxThe Ranbaxy promoters will collect Rs 9,576.3 crore by selling their 34.82% stake in the country's biggest drug maker. Ranbaxy sell-off | A...
- Ranbaxy dismisses reports of Pfizer's bid for stakeJoining forces with Daiichi strengthens Ranbaxy's fledging and expensive efforts to develop original drugs, said CEO Malvinder Singh. Ranba...
- Tax sword hangs over Ranbaxy-Daiichi dealA stock exchange transaction will result in the promoters saving more than Rs 1,000 cr, which they would have to pay if this was an off-mar...
- Ranbaxy promoters may duck capital gains tax, pay STTThe transaction is expected to be routed through the stock exchanges in the form of bulk deals and would only invite the nominal securities...
- DRL describes Ranbaxy, Daiichi deal as path breakingDr Reddy's Laboratory, which defeated Ranbaxy in acquiring German company Betapharm, today said the Ranbaxy-Daiichi deal is "path breaking".
- Ranbaxy promoters press exit, sell stake to DaiichiJapan's Daiichi Sankyo has picked up the promoters' 34.8% stake in Ranbaxy Labs for Rs 737 per share. India's overweight workforce | Lose w...
- Ranbaxy inks two deals with group firmsRanbaxy Laboratories has sold some land and building for Rs 90 crore to a group company, sources said.
- Ranbaxy plans Religare cover for healthcare bizThe Ranbaxy promoter group has started a rebranding exercise for some of its healthcare services companies.
- Ranbaxy may sell stake for Merck bidRanbaxy promoters may sell a stake of their equity to raise money for buying Merck’s generic business.
- Ranbaxy plans retail, education forayThe Ranbaxy group is planning to diversify into two new areas - retail and education. It would set up two separate companies for the new ve...
Load More
